"Rod, are you sure it's MND?" It was James Lance, my former Professor of Neurology (now Professor Emeritus, University of New South Wales), on the telephone. He had just received the letter I sent to all my close friends and colleagues when the diagnosis was confirmed. Jim had always emphasised the importance of leaving no stone unturned before accepting a diagnosis of incurable disease, both in his book on headache — which inspired me to do neurology — and during my subsequent clinical training. However, I had to tell him there was no doubt. Four months previously, I had experienced the sudden dramatic onset of widespread muscle fasciculation, without definite weakness, and, after four weeks of rising anxiety, I took my concerns to a colleague. Although at that stage he reassured me that he had found no definite abnormality, I was concerned that during the examination I had not been able to support my weight on my left leg.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Institute of Neurological Sciences, Prince of Wales Hospital, Randwick, NSW.
- 1. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
- 2. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52: 1311-1323.
- 3. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425-1431.
- 4. Rosenfeld J, King RM, Smith J. A pilot trial of oxandrolone in amyotrophic lateral sclerosis [Abstract]. 13th Annual Symposium on ALS/MND, Melbourne, 2002. Available at: http: //www.mndassociation.org/abstracts2002/Session_5.pdf (accessed Feb 2003).
- 5. van den Bosch L, Tilkin P, Lemmens G, et al. Effect of minocycline on disease onset and mortality in a transgenic model of ALS. [Abstract]. 13th Annual Symposium on ALS/MND, Melbourne, 2002. Available at: http: //www.mndassociation.org/abstracts2002/Poster_Theme_3.pdf (accessed Feb 2003).
- 6. Lyall RA, Donaldson N, Fleming T, et al. A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology 2001; 57: 153-156.
- 7. Bourke SC, Shaw PJ, Gibson GJ. Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS. Neurology 2001; 57: 2040-2044.